Core Insights - The 2024 Veeva R&D and Quality Summit will feature industry leaders from major pharmaceutical companies to discuss advancements in drug development [1][2] - The event aims to enhance collaboration and innovation in the life sciences sector through connected systems across various functions [1][4] Group 1: Event Overview - The Veeva R&D and Quality Summit is one of the largest life sciences events, attracting over 2,000 executives and offering more than 100 sessions [2] - Veeva CEO Peter Gassner will deliver the opening keynote, focusing on how connected data and systems can streamline drug development and accelerate time to market [2] Group 2: Key Presentations - AbbVie and Merck will discuss the transformation of pharmacovigilance and its impact on operational visibility and efficiency [2][3] - Astellas will present its holistic approach to enhancing clinical processes for improved speed and transparency [3] - Eikon Therapeutics will highlight the importance of establishing a scalable foundation for efficient development from clinical trials to product launch [3] Group 3: Innovations in Quality Control - Neurogene and Verve Therapeutics will address modernizing quality control through simplified processes and digital-first execution [3] - Sanofi will showcase the use of AI-powered translation to expedite submission timelines [3] - UCB will share its journey in enterprise eCOA to standardize patient data capture and accelerate delivery [4] Group 4: Veeva's Commitment - Veeva Systems emphasizes its commitment to customer success by providing integrated software, data, and services to advance innovation in the life sciences [4] - The summit serves as a platform for sharing learnings, fresh ideas, and strategies to improve collaboration and accelerate the delivery of novel products [4]

PLEASANTON, Calif., Aug. 7, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its second quarter, which ended July 31, 2024, after market close on August 28, 2024. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results. Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com approximately at 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website followi ...

Veeva Systems (VEEV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this provider of cloud-based software services for the life sciences industry have returned +5.9% over the past month versus the Zacks S&P 500 composite's +1.1% change. The Zacks Internet - Software industry, to which Veeva belongs, has lost 6.4% over this period. Now the key question is: Where could ...

Core Insights - Veeva Systems' latest report indicates that targeted pre-launch scientific outreach significantly enhances the impact of medical affairs teams on treatment adoption, with biopharmas investing in these activities achieving 40% faster adoption rates compared to those that invest less [1][6]. Group 1: Pre-launch Scientific Outreach - Companies that engage key experts at congresses, develop clinical guidelines, and secure publication coverage before product launch experience a 40% faster treatment adoption [6]. - Investment in pre-launch congress activities has the strongest influence on treatment decisions post-approval, surpassing the impact of clinical guidelines and publications [6]. - Engaging early-career healthcare professionals (HCPs) is crucial, as they are four times more likely to initiate patients on new treatments and significantly more active in congress participation and digital engagement [6]. Group 2: Influence of Congresses and Early-career Experts - Congresses and the subsequent digital discussions are pivotal in increasing scientific awareness and facilitating impactful medical conversations [5][6]. - Early-career HCPs are five times more likely to speak at congresses, eleven times more likely to engage digitally, and seven times more likely to publish their findings [6]. - The analysis is based on over 600 million HCP interactions and activities from more than 80% of commercial biopharma field teams globally, making it a comprehensive industry benchmark [9].

Core Insights - Neuraxpharm will implement Veeva Vault QualityDocs and Veeva Vault Training to enhance its quality operations and compliance [1][5] - The partnership aims to improve oversight, inspection readiness, and collaboration across Neuraxpharm's network of over 100 contract development and manufacturing organizations (CDMOs) [1][2] Company Overview - Neuraxpharm is a leader in the pharmaceutical industry, focusing on disorders affecting the central nervous system (CNS) [2] - Veeva Systems is recognized as a global leader in cloud software for the life sciences sector, serving over 1,000 customers, including major biopharmaceutical companies and emerging biotechs [5] Product Features - Veeva Vault QualityDocs facilitates efficient GxP content management and information sharing across Neuraxpharm's sites [2] - Veeva Vault Training allows Neuraxpharm to deploy training and curricula to ensure GxP compliance [2] - The integration of these applications is expected to streamline content and training, enabling Neuraxpharm to scale its operations as it expands its product portfolio [5]

Company Insights - Boston Scientific has a Zacks Rank of 2 and an estimated long-term growth rate of 12.5% [1] - Boston Scientific's earnings have exceeded estimates in the last four quarters, with an average surprise of 7.5% [1] - Boston Scientific's shares have increased by 46.3% over the past year, contrasting with a 1.8% decline in the industry [2] Veeva Systems Developments - Veeva Systems has partnered with Vita Global Sciences to enhance clinical data management processes [3] - The adoption of Veeva Vault EDC is expected to improve Vita Global's study designs and data management efficiency [4][5] - Veeva Systems' management anticipates that the partnership will accelerate study builds and improve patient outcomes [5] Industry Prospects - The global clinical data management system market is projected to grow from $2.3 billion in 2022 to $5.42 billion by 2030, with a CAGR of 11.3% [6] - The growth is driven by an increasing number of clinical trials and integration with healthcare technologies [6] - The recent product adoption is expected to enhance Veeva Systems' global business [7] Notable Developments - Veeva Vault EDC was selected by Hangzhou Tigermed Consulting as its technology foundation for modern EDC [8] - Veeva Systems announced that three top 20 biopharmas selected multiple Veeva Development Cloud Applications in the first quarter of fiscal 2025 [8] - Veeva Vault Basics, a new offering for biotechs, was launched and is currently available in North America [9] Price Performance - Veeva Systems' shares have decreased by 5.8% over the past year, while the industry has risen by 22.3% and the S&P 500 by 22.6% [10]

Core Viewpoint - Veeva Systems is expected to show strong earnings growth in its upcoming release, with significant increases in both EPS and revenue compared to the previous year [2][8]. Company Performance - Veeva Systems' stock closed at $180.43, reflecting a -0.82% change, which underperformed against the S&P 500's loss of 0.78% on the same day [1]. - Over the past month, Veeva's shares gained 1.78%, outperforming the Computer and Technology sector's decline of 3.17% but lagging behind the S&P 500's increase of 2.14% [7]. Earnings Estimates - The consensus estimate for Veeva's upcoming earnings per share (EPS) is $1.53, representing a growth of 26.45% year-over-year [2]. - Quarterly revenue is projected to be $667.3 million, which is a 13.06% increase from the same quarter last year [2]. - For the entire year, the Zacks Consensus Estimates forecast earnings of $6.15 per share and revenue of $2.71 billion, indicating increases of 27.07% and 14.47%, respectively, compared to the previous year [8]. Analyst Sentiment - Recent changes to analyst estimates for Veeva Systems indicate a positive outlook, reflecting optimism about the company's business and profitability [3]. - The Zacks Consensus EPS estimate has seen a 0.34% increase over the last 30 days, suggesting a favorable shift in analyst sentiment [4]. Valuation Metrics - Veeva Systems has a PEG ratio of 1.22, which is lower than the industry average PEG ratio of 1.77, indicating a potentially attractive valuation relative to its growth prospects [5]. - The company holds a Forward P/E ratio of 29.59, which is in line with the industry average [10]. Industry Context - The Internet - Software industry, which includes Veeva Systems, ranks in the top 36% of all industries according to the Zacks Industry Rank, suggesting a strong performance relative to other sectors [11].

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. What are the Zacks Style Scores? Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, an ...

Veeva Systems Inc. (VEEV) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism led by a solid first-quarter fiscal 2025 performance and strategic deals are expected to contribute further. Stiff competition and data security threats persist. Image Source: Zacks Investment Research Over the past year, this Zacks Rank #3 (Hold) stock has lost 9.2% against 20.8% growth of the industry and a 25.1% rise of the S&P 500 Composite. In the first quarter of fiscal 20 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Score ...